Retreat Study
27 January 2025
Repurposing anti-retroviral drugs to treat NF2 related tumours
.png)


Repurposing anti-retroviral drugs to treat NF2 related tumours
· Do you have NF2-related Schwannomatosis (formerly Neurofibromatosis 2 (NF2)) and skin tumour(s)?
· Are you over 18?
You are invited to take part in a research study being undertaken initially in Plymouth and Manchester, led by Professor C. Oliver Hanemann, a consultant neurologist at the Peninsula Medical School in Plymouth.
Although needed, there is currently no drug treatment for tumours in patients with NF2. Oliver Hanemann’s research group has identified two new candidate drugs.
In this small study, skin nerve tumour biopsies and blood samples from up to 16 participants, taken before and after treatment, will be analysed. This will quickly indicate whether the drug candidates should be tested in larger trials. Although there is no immediate benefit from taking part in the study, the results of the study may help NF2 patients in the future.
If you would like to find out more about the study, please contact Professor Hanemann.
His contact details are:
Professor C. Oliver Hanemann MD FRCP
Email: Oliver.Hanemann@plymouth.ac.uk
or
Hannah Kane
Assistant Practitioner for Research
University Hospitals Plymouth NHS Trust
Tel: 01752 433714
Email: hannah.kane2@nhs.net